Clinical trial
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine…
NCT00003425 · University of Kentucky, Other · Completed
Key facts
| NCT number | NCT00003425 |
|---|---|
| Title | Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect |
| Official title | Phase I/II Study of Escalating Dose Melphalan With Autologous Pluripotent Hematopoietic Stem Cell Support and Amifostine Cytoprotection in Cancer Patients |
| Lead sponsor | University of Kentucky, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Leukemia, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, amifostine trihydrate, cyclophosphamide, melphalan, peripheral blood stem cell transplantation |
| Enrollment | 25 |
| Start date | Dec 1, 1997 |
| Primary completion | Jul 1, 2002 |
| First posted | Feb 20, 2004 |
| Last update posted | Apr 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: